News
Our peptide manufacturing facility at Changzhou site has successfully passed the Pre-Approval Inspection by Japan Pharmaceuticals and Medical Devices Agency (PMDA) for an innovative peptide…
Our peptide manufacturing facility at Changzhou site has successfully passed the Pre-Approval Inspection by Japan Pharmaceuticals and Medical Devices Agency (PMDA) for an innovative peptide drug. The 3-day inspection, without any major findings, highlighted our commitment to quality and excellence in peptide production.
Since January 2024, we’ve tripled our solid-phase peptide synthesis capacity to more than 32,000 L across our Changzhou and Taixing sites, and more capacities will be added in Taixing and Singapore to accelerate peptide drugs to patients.
Keep reading
Shanghai, China – April 1, 2025 — WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences…
Couvet, Switzerland – November 14, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life…
First operational building dedicated to API development for oligonucleotides, peptides, and complex synthetic conjugates.
How can we help?
Tell us where your molecule is today — discovery, CMC, or commercial supply — and we will map the fastest credible route to patients.
Small molecule projects? WuXi STA